The UK-based pharmaceutical company GlaxoSmithKline made waves last week with the announcement that it was seeking regulatory approval for the world’s first-ever malaria vaccine. GSK hopes that its vaccine, called ‘RTS,S,’ will prevent millions of malaria cases each year.
Meanwhile, researchers in Tanzania said this week they have made strides in developing an important research tool that they hope will significantly contribute to developing anti-malarial drugs and vaccines suited to the African population.
Both recent advents in the field of malarial research hold promise in tackling one of the world’s deadliest diseases. But there’s still a long way to go before eradicating malaria, experts say.